Merck's Q1 2011 earnings call highlights strong performance, driven by growth in key products like JANUVIA, JANUMET, and others.  Management expresses confidence in the company's growth strategy, including investments in emerging markets and new product launches.  The call also touches upon cost-cutting measures and the impact of patent expirations.  This likely signals a positive near-term outlook for the stock.
[1]
